Literature DB >> 26294729

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.

Efstathios Kastritis1, Marie-Christine Kyrtsonis2, Pierre Morel3, Maria Gavriatopoulou4, Evdoxia Hatjiharissi5, Argirios S Symeonidis6, Amalia Vassou7, Panagiotis Repousis8, Sossana Delimpasi9, Anastasia Sioni10, Evrydiki Michalis11, Michail Michael12, Elina Vervessou13, Michael Voulgarelis14, Costantinos Tsatalas15, Evangelos Terpos4, Meletios A Dimopoulos4.   

Abstract

Entities:  

Keywords:  Rituximab; age; cyclophosphamide; fludarabine; lymphoma; prognosis

Mesh：

Substances：

Year:  2015        PMID： 26294729      PMCID： PMC4825312          DOI： 10.3324/haematol.2015.124149

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  When is a death from prostate cancer not a death from prostate cancer?

Authors:  P Albertsen
Journal:  J Natl Cancer Inst       Date:  2000-04-19       Impact factor: 13.506

Review 2.  Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Robert A Kyle; Steven P Treon; Raymond Alexanian; Bart Barlogie; Magnus Björkholm; Madhav Dhodapkar; T Andrew Lister; Giampaolo Merlini; Pierre Morel; Marvin Stone; Andrew R Branagan; Véronique Leblond
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

3.  International prognostic scoring system for Waldenstrom macroglobulinemia.

Authors:  Pierre Morel; Alain Duhamel; Paolo Gobbi; Meletios A Dimopoulos; Madhav V Dhodapkar; Jason McCoy; John Crowley; Enrique M Ocio; Ramon Garcia-Sanz; Steven P Treon; Veronique Leblond; Robert A Kyle; Bart Barlogie; Giampaolo Merlini
Journal:  Blood       Date:  2009-02-05       Impact factor: 22.113

4.  Competing risk analysis using R: an easy guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2007-06-11       Impact factor: 5.483

5.  Comorbidity and competing risks for mortality in men with prostate cancer.

Authors:  Timothy J Daskivich; Karim Chamie; Lorna Kwan; Jessica Labo; Atreya Dash; Sheldon Greenfield; Mark S Litwin
Journal:  Cancer       Date:  2011-04-08       Impact factor: 6.860

6.  Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.

Authors:  Judith M Bliss; Lucy S Kilburn; Robert E Coleman; John F Forbes; Alan S Coates; Stephen E Jones; Jacek Jassem; Thierry Delozier; Jørn Andersen; Robert Paridaens; Cornelis J H van de Velde; Per E Lønning; James Morden; Justine Reise; Laura Cisar; Thomas Menschik; R Charles Coombes
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

7.  Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study.

Authors:  Rohit P Ojha; Christina A Hanzis; Zachary R Hunter; Sander Greenland; Tabatha N Offutt-Powell; Robert J Manning; Megan Lewicki; Philip S Brodsky; Leukothea Ioakimidis; Christina K Tripsas; Christopher J Patterson; Patricia Sheehy; Karan P Singh; Steven P Treon
Journal:  Cancer Epidemiol       Date:  2011-11-17       Impact factor: 2.984

8.  Risk of second cancers in Waldenström macroglobulinemia.

Authors:  M Varettoni; A Tedeschi; L Arcaini; C Pascutto; E Vismara; E Orlandi; F Ricci; A Corso; A Greco; S Mangiacavalli; M Lazzarino; E Morra
Journal:  Ann Oncol       Date:  2011-04-27       Impact factor: 32.976

9.  Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.

Authors:  Irene M Ghobrial; Rafael Fonseca; Morie A Gertz; Matthew F Plevak; Dirk R Larson; Terry M Therneau; Robert C Wolf; Randi J Hoffmann; John A Lust; Thomas E Witzig; Martha Q Lacy; Angela Dispenzieri; S Vincent Rajkumar; Stephen R Zeldenrust; Philip R Greipp; Robert A Kyle
Journal:  Br J Haematol       Date:  2006-04       Impact factor: 6.998

10.  Choice and interpretation of statistical tests used when competing risks are present.

Authors:  James J Dignam; Maria N Kocherginsky
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544
View more
  6 in total

1.  Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.

Authors:  Adam J Olszewski; Steven P Treon; Jorge J Castillo
Journal:  Oncologist       Date:  2016-07-29

2.  Disease control should be the goal of therapy for WM patients.

Authors:  Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Blood Adv       Date:  2017-11-28

3.  Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.

Authors:  Akio Saito; Atsushi Isoda; Masaru Kojima; Akihiko Yokohama; Yutaka Tsukune; Makoto Sasaki; Shigeki Ito; Akihiro Ohtsu; Michiaki Koike; Kayoko Murayama; Keiichi Moriya; Hideto Tamura; Morio Matsumoto; Hirotaka Nakahashi; Sakae Tanosaki; Tohru Sakura; Toshihide Kawamura; Tomomi Miyanaga; Naoya Nakamura; Hirokazu Murakami; Hiroshi Handa; Norifumi Tsukamoto
Journal:  Int J Hematol       Date:  2017-07-07       Impact factor: 2.490

4.  Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis.

Authors:  Yan-Hua Zheng; Li Xu; Chun Cao; Juan Feng; Hai-Long Tang; Mi-Mi Shu; Guang-Xun Gao; Xie-Qun Chen
Journal:  Onco Targets Ther       Date:  2019-04-11       Impact factor: 4.147

Review 5.  How I treat elderly patients with plasma cell dyscrasias.

Authors:  Maria Gavriatopoulou; Despoina Fotiou; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Evangelos Terpos; Meletios Athanasios Dimopoulos
Journal:  Aging (Albany NY)       Date:  2018-12-18       Impact factor: 5.682

6.  Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.

Authors:  Nicole H Dalal; Graça M Dores; Rochelle E Curtis; Martha S Linet; Lindsay M Morton
Journal:  Br J Haematol       Date:  2020-02-23       Impact factor: 8.615
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.